Lu-PSMA-617 (Pluvicto)

Lutetium-177-PSMA-617 · Novartis (Advanced Accelerator Applications)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lu-PSMA-617 (Pluvicto), covering 2025-12-03 to 2025-12-03. Get the full timeline:

Most recent: Clinical Trial Update: Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST) [Phase 2]